Serina Therapeutics (Serina Therapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics COGS-to-Revenue?

Serina Therapeutics's Cost of Goods Sold for the six months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the six months ended in Mar. 2024 was $0.00 Mil.

Serina Therapeutics's COGS to Revenue for the six months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Serina Therapeutics's Gross Margin % for the six months ended in Mar. 2024 was N/A%.

Serina Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Serina Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics COGS-to-Revenue Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

COGS-to-Revenue

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Mar24
COGS-to-Revenue	-	-	-	-	-

Serina Therapeutics COGS-to-Revenue Calculation

Serina Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.5
	=	0.00

Serina Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Serina Therapeutics (AMEX:SER) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Serina Therapeutics's Gross Margin % for the six months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Serina Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024